On April 26, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, reported it has entered into a definitive securities purchase agreement for the sale of its equity securities in a private placement with certain accredited investors for gross proceeds to Immunome of approximately $27 million, before deducting placement agent commissions and other offering expenses (Press release, Immunome, APR 26, 2021, View Source [SID1234578497]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement provides for the sale of an aggregate of 1,000,000 units at a price of $27.00 per unit. Each unit consists of one share of Immunome’s common stock and a warrant to purchase one half of a share of common stock at an exercise price of $45.00.
Ladenburg Thalmann & Co. Inc. acted as Immunome’s placement agent in the transaction.
Immunome intends to use the net proceeds to accelerate the development of its oncology and infectious disease portfolio, including COVID-19, and for other general corporate purposes.
The private placement is expected to close on or about April 28, 2021, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by Immunome with the Securities and Exchange Commission ("SEC").
The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Immunome has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement and upon exercise of the warrants.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.